期刊文献+

EB病毒LMP2-LMP1Δ融合基因免疫效果的初步研究 被引量:7

Construction and preliminary immunological study of EB virus LMP2-LMP1Δ fusion gene
原文传递
导出
摘要 目的构建EBV LMP2-LMP1Δ融合基因,初步观察融合基因体内诱导EBV特异性细胞免疫应答的效果。方法 (1)应用PCR方法构建包含EBV-LMP2全长和去除致癌基因的EBV-LMP1Δ融合基因,并将融合基因插入到pcDNA3.1(+)-his真核表达载体中,构建重组表达质粒pcDNA-LMP2-LMP1Δ,Western blot和免疫荧光方法检测融合蛋白的表达。(2)使用pcDNA-LMP2-LMP1Δ及携带LMP1Δ和LMP2基因的重组腺病毒单独或联合免疫Balb/c小鼠,末次免疫1周后应用IFN-γELISPOT方法检测小鼠脾淋巴细胞中EBV特异性CTL水平。结果 (1)真核表达质粒pcDNA-LMP2-LMP1Δ能够在293细胞中表达LMP2-LMP1Δ融合蛋白,融合蛋白分子量大小正确,具有免疫原性。(2)重组质粒pcDNA-LMP2-LMP1Δ免疫小鼠能够诱导出EBV特异性的CTL,但诱导的CTL水平很低,1×106小鼠脾淋巴细胞中平均斑点数只有12个,远远低于LMP1Δ、LMP2重组腺病毒平均495个斑点数的免疫结果。但使用pcDNA-LMP2-LMP1Δ和重组腺病毒联合免疫,与只使用重组腺病毒相比,诱导的EBV特异性CTL水平能够显著提高,1×106小鼠脾淋巴细胞中平均斑点数可达1 001个(P<0.01)。结论构建的EBV LMP2-LMP1Δ融合基因能够有效表达LMP2-LMP1Δ融合蛋白,并能够在小鼠体内诱导出EBV特异性的CTL反应,与重组腺病毒联合使用,可以提高特异性CTL应答水平。 Objective To construct EBV LMP2-LMP1Δ fusion gene and preliminarily investigate an induced EBV-specific cellular immunological response in vivo.Methods A eukaryotic expression vector was constructed by inserting pcDNA3.1(+)-his plasmid of the fusion gene of full-length EBV-LMP2Δ and partial sequence of EBV-LMP1Δ,later of which had been removed of oncogene.The expression of fusion protein was determined by Western blot analysis and immunofluorescence essay in 293 cell line.Balb/c mice were divided into 4 groups and immunized with PBS,pcDNA3.1-LMP2-LMP1Δ,adenovirus carrying LMP1Δ /LMP2 genes and the combination of pcDNA3.1-LMP2-LMP1Δ(wk 0,2) and the recombinant adenovirus(wk 4),respectively.The EBV-specific CTL levels of the mouse spleen lymphocytes were analyzed with IFN-γ ELISPOT essay in one week after the final immunization.Results The reconstructed pcDNA3.1-LMP2-LMP1Δ-his expressed the LMP2-LMP1Δ fusion protein in 293 cells correctly per MW and immunogenicity.The induced EBV-specific CTL response was lower in the mice immunized with the recombinant plasmid pcDNA3.1-LMP2-LMP1Δ-his alone(12 spots/1×106 mouse spleen lymphocytes on average) than that in the mice immunized with the recombinant adenovirus vector vaccine(495 spots/1×106 mouse spleen lymphocytes spots on average).However,the induced EBV-specific CTL response was greatly improved(1 001 spots/ 1×106 mouse spleen lymphocytes on average) when mice were immunized with the combination of pcDNA3.1-LMP2-LMP1Δ-his and the recombinant adenovirus(P0.001).Conclusions The new reconstructed EBV LMP2-LMP1Δ fusion gene eukaryotic expression vector improved the EBV-specific cellular CTL response when used together with recombinant adenovirus vaccine.
出处 《中国病毒病杂志》 CAS 2011年第1期45-50,共6页 Chinese Journal of Viral Diseases
基金 国家"863"基金资助项目(2006AA02A229)
关键词 EB病毒 潜伏膜蛋白1 潜伏膜蛋白2 融合基因 EB virus Latent membrane protein 1 Latent membrane protein 2 Fusion gene
  • 相关文献

参考文献11

  • 1左建民,周玲,王琦,曾毅.含EBV-LMP2基因重组腺病毒疫苗的构建及其诱导CTL应答的初步探讨[J].中华微生物学和免疫学杂志,2003,23(6):446-449. 被引量:9
  • 2周玲,姚庆云,Steve.Lee,A.Rickinson,曾毅.鼻咽癌病人和正常人群中EB病毒特异性T细胞对靶抗原的识别和应答[J].病毒学报,2001,17(1):7-10. 被引量:13
  • 3Lammali FS,Djennaoui D,Belaoui H,et al.Transcriptionalexpression of Epstein-Barr virus genes and proto-oncogenes inNorth African Nasopharyngeal carcinoma. Journal of Medical Virology . 1996
  • 4Lutzky VP,Corban M,Heslop L,et al.Novel approach tothe formalation of an Epstein-Barr virus antigen-based nasopha-ryngeal carcinoma viccine. Journal of Virology . 2010
  • 5Excler JL.AIDS vaccine development:perspectives,challengesand hopes. Indian Journal of Medical Research . 2005
  • 6Konishi K,Maruo S,Kato H,et al.Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. Journal of General Virology . 2001
  • 7Karin C,Straathof,Ann ML,et al.Characterization of Latent Membrane Protein -Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma. Journal of Immunology . 2005
  • 8Jeon YK,Lee BY,Ki mJE,et al.Molecular characterization of Epstein-Barr virus a-nd oncoprotein expression in nasopha-ryngeal carcinoma in Korea. Head and Neck . 2004
  • 9DuraiswamyJ,BharadwajM,TellamJ,etal.InductionoftherapeuticT-cellresponsestosubdominanttumor-associatedviraloncogeneafterimmunizationwithreplication-incompetentpolyepitopeadenovirusvaccine. Cancer Research . 2004
  • 10Taylor GS,Haigh TA,Gudgeon Nh,et al.Dual Stimulation of Epstein-Barr Virus (EBV) -Specific CD4( + ) and CD8( + )-T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal Carcinoma. Journal of Virology . 2004

二级参考文献15

  • 1林毓纯 商铭 等.鼻咽癌的细胞免疫及其HLA的限制[J].病毒学报,1982,4(4):254-256.
  • 2He TC, Zhou SD, Costa LT, et al. A simplified system for generating recombinant adenoviruses. Pro Natl Acad Sei, USA, 1998, 95: 2509-2514.
  • 3Huang DP. Epidemiology and etiology. In: van-Hasselt CA, Gibb AG,eds. Nasopharyngeal carcinoma. Chinese University Press,Hong Kong,1991, p23.
  • 4Rooney CM, Smith CA. Use of gene-modifled virus-specific T lymphocytes to control Epstein-Barr virus related lympholiferation. The Lancet, 1995,345: 9-13.
  • 5Schmidt C, Burrows SR, Sculley riB, et al. Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implication for vaccine strategies. Proc Natl Acad Sci USA, 1991, 88: 9478-9482.
  • 6Butterfield LH, Jilani SM, Chakraborty NG, et. al. Generation of mela-noma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol, 1998, 161: 5607-5613.
  • 7Wan YJ, Bramson B, Carter F, etal. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther. 1997. 8: 1355-1363.
  • 8Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol, 2000, 18: 245-273.
  • 9Redchenko IV, Rickinson AB. Accessing Epstein-Barr vires specific T cell memory with peptide loaded dendritic cells. J Virol, 1999, 73: 334--342.
  • 10周玲,中华实验和临床簿学杂志,2000年,14卷,4期,384页

共引文献19

同被引文献33

引证文献7

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部